Compare AbbVie Inc (ABBV) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Wolfspeed Inc — how do they compare? AbbVie Inc trades at $249.02 (market cap $438.19B), while Wolfspeed Inc trades at $30.27 (market cap $1.52B). The key difference: AbbVie Inc is far larger — about 288.3× Wolfspeed Inc's market cap, and AbbVie Inc pays a 2.79% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals.
| ABBV | WOLF | |
|---|---|---|
Market Cap | $438.19B | $1.52B |
Sector | Health | Technology |
52-Week High | $263.58 | $73.68 |
52-Week Low | $197.38 | $1.19 |
Enterprise Value | $502.45B | $2.18B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $249.94, up 1.59% today, with a bullish technical signal and strong analyst consensus. Recent earnings beats (Q4 2025 to Q2 2026) and a 70.73% buy rating from analysts highlight confidence. Revenue grew to $61.16B in 2025, though net margin dipped to 6.9%, while Skyrizi and Rinvoq drive growth post-Humira patent expiry. A dividend of $1.73 is scheduled for August 2026, supporting income appeal.
Outlook is positive with a $281.33 price target, but risks include high P/E of 70.05, patent cliffs in the 2030s, and regulatory lawsuits. Institutional buying and robust pipeline innovations like ELAHERE® in ovarian cancer offer upside, yet valuation and competitive pressures warrant caution for growth sustainability.
Wolfspeed (WOLF) trades at $32.87, up 19.14% in the past 24 hours, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance, beating estimates in Q3 2025 and Q1 2026 but missing in Q4 2025. Recent news highlights strategic partnerships for AI data center power solutions and a new board appointment. However, the company faces significant financial challenges with negative gross and net income margins.
The outlook is cautiously optimistic due to strong analyst buy ratings and positive technical momentum, but investment is tempered by weak profitability and high execution risks. Key opportunities lie in silicon carbide technology adoption for AI and electrification, while risks include ongoing losses and competitive pressures in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
